Biden administration pushes for Supreme Court to hear Teva vs. GSK 'skinny labels' case.

The Biden Administration has urged the US Supreme Court to hear a patent appeal over drug labels involving Teva Pharmaceuticals and GlaxoSmithKline that could have significant ramifications for the generic-drug industry. The case involves "skinny labels" that allow generic drugmakers to launch their products earlier while avoiding liability for infringing brand-name drugmakers' patents. The US Solicitor General said Teva's generic version of GSK's heart drug Coreg could not have violated GSK's patent rights because Teva omitted the infringing use of the drug from its labeling.